Rania S Nageeb1, Noha A Hashim1, Amal Fawzy2. 1. 1Department of Neurology, Faculty of Medicine, Zagazig University, Sharkia, Egypt. 2. 2Department of Biochemistry, Faculty of Medicine, Zagazig University, Sharkia, Egypt.
Abstract
BACKGROUND: Multiple sclerosis (MS) is a chronic demyelinating central nervous system (CNS) disease. Changes in insulin growth factor 1 (IGF-1) input to the brain can affect survival of myelin and CNS cells. The study aims to investigate the relation of serum IGF-1 levels with cognitive impairment and fatigue in MS patients. METHODS: This study was conducted on 46 MS patients and 46 healthy controls. All participants were subjected to clinical assessment, serum IGF-1 levels, expanded disability status scale (EDSS), modified fatigue impact scale (MFIS), and Montreal cognitive assessment (MoCA) scale. RESULTS: There was no significant difference between patients and controls regarding serum IGF-1 levels (P = 0.19). However, low serum levels of IGF-1 have significantly greater odds for fatigue (P = 0.002) and cognitive impairment (P < 0.001). Also, serum IGF-1 levels have a significant negative correlation with MFIS (r = - 0.701 and P < 0.001) and a significant positive correlation with MoCA scale (r = + 0.84 and P < 0.001). CONCLUSIONS: The results, specifically that low levels of serum IGF-1 was associated with cognitive impairment and fatigue in MS, suggest that IGF-I may be involved in the pathogenesis of cognitive deficits and fatigue in MS disease.
BACKGROUND: Multiple sclerosis (MS) is a chronic demyelinating central nervous system (CNS) disease. Changes in insulin growth factor 1 (IGF-1) input to the brain can affect survival of myelin and CNS cells. The study aims to investigate the relation of serum IGF-1 levels with cognitive impairment and fatigue in MS patients. METHODS: This study was conducted on 46 MS patients and 46 healthy controls. All participants were subjected to clinical assessment, serum IGF-1 levels, expanded disability status scale (EDSS), modified fatigue impact scale (MFIS), and Montreal cognitive assessment (MoCA) scale. RESULTS: There was no significant difference between patients and controls regarding serum IGF-1 levels (P = 0.19). However, low serum levels of IGF-1 have significantly greater odds for fatigue (P = 0.002) and cognitive impairment (P < 0.001). Also, serum IGF-1 levels have a significant negative correlation with MFIS (r = - 0.701 and P < 0.001) and a significant positive correlation with MoCA scale (r = + 0.84 and P < 0.001). CONCLUSIONS: The results, specifically that low levels of serum IGF-1 was associated with cognitive impairment and fatigue in MS, suggest that IGF-I may be involved in the pathogenesis of cognitive deficits and fatigue in MS disease.
Authors: R Lanzillo; C Di Somma; M Quarantelli; A Carotenuto; C Pivonello; M Moccia; A Cianflone; A Marsili; G Puorro; F Saccà; C V Russo; C De Luca Picione; F Ausiello; A Colao; V Brescia Morra Journal: Eur J Neurol Date: 2016-12-16 Impact factor: 6.089
Authors: Diana G Taekema; Carolina H Y Ling; Gerard Jan Blauw; Carel G Meskers; Rudi G J Westendorp; Anton J M de Craen; Andrea B Maier Journal: Eur J Endocrinol Date: 2010-12-06 Impact factor: 6.664
Authors: M T Pellecchia; G Santangelo; M Picillo; R Pivonello; K Longo; C Pivonello; C Vitale; M Amboni; A De Rosa; M Moccia; R Erro; G De Michele; L Santoro; A Colao; P Barone Journal: Eur J Neurol Date: 2013-03-29 Impact factor: 6.089
Authors: Laura D Baker; Suzanne M Barsness; Soo Borson; George R Merriam; Seth D Friedman; Suzanne Craft; Michael V Vitiello Journal: Arch Neurol Date: 2012-11
Authors: M Calabrese; F Rinaldi; I Mattisi; P Grossi; A Favaretto; M Atzori; V Bernardi; L Barachino; C Romualdi; L Rinaldi; P Perini; P Gallo Journal: Neurology Date: 2010-01-26 Impact factor: 9.910
Authors: Carmilla M M Licht; Lise C van Turenhout; Jan Berend Deijen; Lando L J Koppes; Willem van Mechelen; Jos W R Twisk; Madeleine L Drent Journal: Int J Endocrinol Date: 2014-07-10 Impact factor: 3.257
Authors: Andreas Hoeflich; Brit Fitzner; Christina Walz; Michael Hecker; Armin Tuchscherer; Julia Brenmoehl; Uwe Klaus Zettl Journal: Front Endocrinol (Lausanne) Date: 2021-01-05 Impact factor: 5.555